Baptist Health Cancer Care

As these new techniques evolve and we adjust conditioning regimens, induction timing and dosing levels, as well as introducing different drug combinations, we are very hopeful that we will continue to see improved outcomes for hematologic malignancies, says Guenther Koehne, MD, PhD.

During a presentation, Paul G. Richardson, MD, talked about the shift from triplet combination therapies toward quadruplet combinations for the treatment of multiple myeloma.

Adam Cohen, MD, discusses his presentation on updates in BCMA-directed therapies for multiple myeloma, which he gave during the 3rd Summit of the Americas on Immunotherapies for Hematologic Malignancies.

Michael Chuong, MD, discusses the unmet needs for the treatment of inoperable pancreatic cancer.

Treatment locations in New York, New Jersey, and Florida are recruiting patients with mall cell lung cancer to receive olaparib and low-dose radiotherapy in a phase 1 clinical trial.

The treatment of platinum-resistant ovarian cancer is challenging, with limited therapeutic options. Antibody-drug conjugates as single agents or in combinations are showing promise for these patients.

Michael D. Chuong, MD, a radiation oncologist and medical director of Proton Therapy at Miami Cancer Institute, Baptist Health South Florida, discusses the benefits of MRI-guided radiation therapy in pancreatic cancer.

Complete surgical removal of a pancreatic tumor is not possible for most patients. Chemotherapy and radiation therapy are typically recommended to slow tumor growth, but ultimately are not expected to be curative, writes Michael Chuong, MD.

While the volume and variety of information coming from current studies seems overwhelming, it is what is changing the cancer care environment today.